ReportWire

Tag: Vaccines

  • Ron DeSantis’s Surgeon General Tells Parents It’s Okay to Send Their Unvaccinated Kids to School Amid Measles Outbreak

    Ron DeSantis’s Surgeon General Tells Parents It’s Okay to Send Their Unvaccinated Kids to School Amid Measles Outbreak

    [ad_1]

    In 2021, Ron DeSantis appointed Joseph Ladapo the surgeon general of Florida, after Ladapo’s op-eds questioning mask-wearing, COVID-19 vaccines, and other public health measures caught the governor’s eye. In the ensuing years, Ladapo has recommended children should not receive the COVID vaccine, has “weaponize[d] bad science to spread anti-vaccine disinformation as official policy,” and has personally “altered key findings in [a] study on Covid-19 vaccine safety.” Now, Ladapo is bringing his medical point of view to a measles outbreak that he appears happy to let explode on his watch.

    In a letter sent to parents this week, Ladapo alerted them to a cluster of measles cases that had been identified in Manatee Bay Elementary School and wrote that “it is normally recommended that individuals without history of prior infection or vaccination stay home for up to 21 days,” as “up to 90% of individuals without immunity will contract measles if exposed.” Having said that? He’s cool with people sending their unvaccinated children to school, despite that whole thing about 90% of unvaccinated people likely contracting the disease. The Florida Department of Health, Ladapo said, “is deferring to parents or guardians to make decisions about school attendance.”

    Not surprisingly, health experts who actually believe in science have said such guidance is wildly irresponsible, with at least one blaming Ladapo for the outbreak. “The reason why there is a measles outbreak in Florida schools is because too many parents have not had their children protected by the safe and effective measles vaccine,” John P. Moore, a professor of microbiology and immunology at Weill Cornell Medical College, told The Washington Post. “And why is that? It’s because anti-vaccine sentiment in Florida comes from the top of the public health food-chain: Joseph Ladapo.” Dr. Ben Hoffman, president of the American Academy of Pediatrics, told the outlet the guidance from Florida “runs counter to everything I have ever heard and everything that I have read. It runs counter to our policy. It runs counter to what the [Centers for Disease Control and Prevention] would recommend.” (As the Post notes, measles can cause severe health complications, including death.)

    Patsy Stinchfield, president of the National Foundation for Infectious Diseases, told the Post the outbreak will become a major threat to the community if unvaccinated people who’ve been exposed to the disease don’t follow health recommendations like staying at home during the time they may be contagious. In other words, things could get a lot worse if people listen to the Florida surgeon general.

    Ladies and gentlemen, the modern Republican Party

    X content

    This content can also be viewed on the site it originates from.

    Nothing to see here, just the front-runner for the GOP nomination appearing to suggest he’s got blackmail material on his opponent

    X content

    This content can also be viewed on the site it originates from.

    Elsewhere!

    Biden announces more than 500 sanctions on Russia after Navalny’s death

    NBC News • Read More

    Ohio GOP Senate candidates pitch federal abortion bans even after voters protected reproductive rights

    NBC News • Read More

    An ectopic pregnancy put her life at risk. A Texas hospital refused to treat her.

    The Washington Post • Read More

    Major Embryo Shipping Company Halts Business in Alabama

    NYT • Read More

    Michael Cohen’s Moment of Truth Has Arrived

    New York • Read More

    How Did Haley’s South Carolina Become Trump Country? Ask the Tea Party.

    NYT • Read More

    Republicans struggle to escape their Biden impeachment quagmire

    The Washington Post • Read More

    Guinness World Records revokes title for oldest dog ever

    UPI • Read More

    [ad_2]

    Bess Levin

    Source link

  • Measles Strikes a Florida Elementary School With Over 100 Unvaccinated Kids

    Measles Strikes a Florida Elementary School With Over 100 Unvaccinated Kids

    [ad_1]

    Florida health officials on Sunday announced an investigation into a cluster of measles cases at an elementary school in the Fort Lauderdale area with a low vaccination rate, a scenario health experts fear will become more and more common amid slipping vaccination rates nationwide.

    On Friday, Broward County Public School reported a confirmed case of measles in a student at Manatee Bay Elementary School in the city of Weston. A local CBS affiliate reported that the case was in a third-grade student who had not recently traveled. On Saturday, the school system announced that three additional cases at the same school had been reported, bringing the current reported total to four cases.

    On Sunday, the Florida Department of Health in Broward County (DOH-Broward) released a health advisory about the cases and announced it was opening an investigation to track contacts at risk of infection.

    At Manatee Bay Elementary School, the number of children at risk could be over 100 students. According to a Broward County vaccine study reported by the local CBS outlet, only 89.31 percent of students at Manatee Bay Elementary School were fully immunized in the 2023/2024 school year, which is significantly lower than the target vaccination coverage of 95 percent. The school currently has 1,067 students enrolled, suggesting that up to 114 students are vulnerable to the infection based on their vaccination status.

    Measles is one of the most contagious viruses known. It spreads via respiratory and airborne transmission. The virus can linger in air space for up to two hours after an infected person has been in an area. People who are not vaccinated or have compromised immune systems are susceptible, and up to 90 percent of susceptible people exposed to the virus will become infected. Measles symptoms typically begin around eight to 14 days after exposure, but the disease can incubate for up to 21 days. The symptoms begin as a high fever, runny nose, red and watery eyes, and a cough before the telltale rash develops. Infected people can be contagious from four days before the rash develops through four days after the rash appears, according to the Centers for Disease Control and Prevention. About 1 in 5 unvaccinated people with measles are hospitalized, the CDC adds, while 1 in 20 infected children develop pneumonia and up to 3 in 1,000 children die of the infection.

    Those who are not immunocompromised and are fully vaccinated against measles (who have received two doses of the Measles, Mumps, and Rubella (MMR) vaccine) are generally not considered at risk. The two doses are about 97 percent effective at preventing measles, and protection is considered to be life-long.

    The DOH-Broward said it is now “identifying susceptible contacts that may be candidates for post-exposure prophylaxis through MMR or immunoglobulin.”

    While the risk of measles is generally low in the US—the country declared it eliminated in 2000—the threat of large outbreaks is growing as vaccination rates slip. Many cases in the US are linked to travel from countries where the virus still circulates. But, if a travel-related case lands in a pocket with low vaccination coverage, the virus can take off. Such was the case in 2019, when the country tallied 1,274 measles cases and nearly lost its elimination status.

    Health officials typically consider vaccination coverage of 95 percent or greater sufficient to protect from ongoing transmission. In the years since the COVID-19 pandemic began, vaccination rates among US kindergarteners have slipped to 93 percent, and vaccination exemptions reached an all-time high in the latest data from the 2022-2023 school year. There are now at least 10 states that have vaccination exemption rates above 5 percent, meaning that even if every non-exempt child is vaccinated, those states will not have enough coverage to reach the 95 percent target.

    The CDC has tallied 20 measles cases in the US so far this year. But that is the tally as of February 15; it does not include any of the Florida cases reported since Friday. In 2023, there were 58 measles cases reported to the CDC.

    This story originally appeared on Ars Technica.

    [ad_2]

    Beth Mole, Ars Technica

    Source link

  • The Millionaire LimeWire Founder Behind RFK Jr.

    The Millionaire LimeWire Founder Behind RFK Jr.

    [ad_1]

    Robert F. Kennedy Jr. at a rally in Grand Rapids, Michigan last week.
    Photo: Emily Elconin/Getty Images

    The commercial just before the Super Bowl halftime show urging millions of Americans to vote for Robert F. Kennedy Jr. as an independent was a clever re-creation of his uncle John F. Kennedy’s presidential ad from 1960. But the comparison between the two politicians frustrated some family members whose name was sung repeatedly in the 30-second spot. Kennedy’s cousin Bobby Shriver wrote that his mother, whose image appears in the ad, would be “appalled” by the “deadly health care views” held by RFK Jr., who has spent decades promoting debunked claims about vaccines.

    Kennedy apologized, explaining that he was not aware of the ad’s contents as federal laws prohibit him from coordinating with the super-PAC that paid $7 million for the commercial. But Mark Gorton, the co-founder and co-chair of the PAC, American Values 2024, was not afraid to hit the Kennedy clan harder. “It’s really a shame that a bunch of them are caught so deeply in the Democratic censorship bubble that they don’t understand the real righteousness of the work that RFK Jr. has been doing,” Gorton says. “They are still following the big-pharma party line.”

    For almost three years, Gorton, a hedge-fund multimillionaire, has been one of the great boosters of Kennedy, the exiled member of an American royal family who’s crusading against the pharmaceutical industry and government-funded health programs. Since 2021, Gorton has reportedly donated over $1 million to Children’s Health Fund, the nonprofit chaired by Kennedy that has been accused of promoting disproven anti-vaxx ideas. In 2022, after a private dinner, Kennedy told his inner circle he was considering a presidential run. Gorton vowed to help in any way he could: “I was one of the early people that found out, and I said, ‘If you’re running for president, I’m all in.’”

    Kennedy, 70, has other wealthy backers from high society. Banking heir Timothy Mellon — the largest donor to Donald Trump’s super-PAC last year — has given $15 million to American Values 2024. Abby Rockefeller, the daughter of former Chase CEO David Rockefeller, has given $100,000. But few other donors have been as critical to the campaign as Gorton, who co-founded the PAC and pitched in $500,000 to support the campaign in its nascent days. (The other co-founder, Tony Lyons, is the publisher of the conservative book imprint Skyhorse Publishing, which has put out Kennedy’s most recent books.) Gorton says he was the de facto manager of the working group that got the campaign moving before its formal launch last year.

    Insurgent presidential campaigns are rarely smooth operations, and this one is no exception. Kennedy first ran for the Democratic nomination against Joe Biden, but after getting little traction in polls, he announced he would run as an independent. (He has also flirted with running for the Libertarian nomination to ensure that he got ballot access, which is considerably more difficult without a party.) Gaffes ensued. Epstein connections were revisited. Still, though, he has Super Bowl–level name recognition and is performing well enough in national polls to threaten Biden’s or Trump’s chances at retaking the White House. But Democrats seem more worried about Kennedy and are striking at him hard. Last week, the Democratic National Committee filed a complaint with the Federal Election Commission alleging that American Values 2024 was illegally coordinating with the Kennedy campaign by spending $15 million to get him on the ballot in battleground states such as Arizona, Georgia, Nevada, and Michigan.

    “They have hundreds of millions of dollars at their disposal and they’re willing to play dirty and they consider RFK Jr. to be a very significant threat and they’re desperate,” Gorton says of the DNC.

    He is also ready to defend Kennedy on more controversial matters, such as when the candidate was caught on tape at a private dinner last July saying that COVID was “targeted to attack Caucasians and Black people” and that the “people who are most immune are Ashkenazi Jews and Chinese.”

    “I think there is some dream among the mad scientists inside the biowarfare Establishment to be able to develop targeted diseases that would only kill certain groups of people,” Gorton says, backing up the thrust of Kennedy’s claim. “And we know that that’s their dream. And we also know that the COVID disease was developed in a biowarfare lab in China. And so he was just making the observation that COVID seemed to target certain groups more than others.”

    For Gorton, the response to Kennedy’s COVID comment was a telling look inside the news business. “Here’s all sorts of people who are functionally paid operatives of the DNC who are seeded throughout the media, and they’re just happy to take any sort of story like that, whether it’s true or not, and blow it out of proportion,” he says. “There’s a giant political hit machine out there, and the Democrats are not staying in power by putting forward a superior candidate and doing a good job representing the American people. They’re staying in power by running a giant propaganda hit machine and trying to subvert the mechanisms of democracy and keep RFK Jr. off the ballot.”

    Gorton, who says he is involved in big-picture “strategic guidance” at the PAC, says it is committed to getting Kennedy on the ballot. That may involve spending more of his money. Gorton said in an interview last year that he did not plan on donating again to Kennedy, but he may have changed his mind on that front. “I think I might very well,” he says.

    Gorton is relatively new to politics, having started his career on Wall Street. In 1998, he founded Tower Research Capital, one of the first firms to focus on high-frequency trading. Within a decade, his firm reportedly had over $117 million in assets.

    Mark Gorton in LimeWire’s New York office in 2010.
    Photo: Ramin Talaie/Corbis via Getty Images

    He has extracurricular interests, too. A devoted bicyclist frustrated by car congestion in New York City, Gorton founded an urbanist nonprofit in 1999 that advocated for pedestrian safety and more bike lanes. The group eventually launched the popular transportation site Streetsblog, for which he remains the publisher.

    But Gorton would have been just another millionaire with a nonprofit if not for LimeWire, the peer-to-peer sharing service he founded in 2000. For tens of millions of young users of its free and premium services, it was a portal into a world of easily accessible music, movies, and pornography. It was also a preview of the streaming age to come. “I saw it very much as a First Amendment thing,” says Gorton. “We were creating a tool that let people share files, any sort of files, and that seems like a basic logical extension of the First Amendment.”

    According to the major record labels that sued him, LimeWire was also a massive exercise in copyright infringement. After a federal judge found the company and Gorton personally liable for violating copyright law, his attorneys settled. LimeWire would shut down and pay out $105 million in damages. “Through that experience, I saw that our legal system is not developed off of rational reasoning, based off of the Bill of Rights, but instead has been more or less constructed to support the property interests of large corporations,” Gorton says.

    He was learning other lessons at this time. Around 2007, after reading Robert Caro’s famous series of books on Lyndon B. Johnson, Gorton realized LBJ was behind the JFK assassination. “He describes the character of LBJ, and just how ruthless and power hungry he was, and how, even in college, he’s running fairly sophisticated political conspiracies,” says Gorton. “And through that, I was able to see or get hints that he was behind the Kennedy assassination. Then when I looked more deeply into it, sure enough, there was a mountain of supporting evidence for that.”

    Gorton has discussed this conspiracy theory with Kennedy but treads lightly: “For me, it’s a historical event. For him, it’s his dad and his uncle.” He also says Kennedy “really understands the depth and corruption of the deep state. And this includes the fact that the CIA and Lyndon Johnson and the political Establishment killed his uncle and killed his dad.” (Kennedy has maintained that Sirhan Sirhan, the man convicted of assassinating his father during his presidential run in 1968, is innocent.)

    Gorton says that he did not have a similar a-ha text for his realizations about the pharmaceutical industry’s influence over American politics, only that he has read widely in the field. “I have several shelves in my library filled with books about pharmaceutical-industry corruption,” he says. “Also, I read a lot of Substacks. I found that basically Substack is the place where I think some of the best independent voices are. And it’s a corner of the internet that is not completely dominated by corporate interests.”

    Gorton’s own Substack page provides a clue to his current beliefs on vaccines and the government’s response to COVID. “You can no more expect to hear the truth from the CDC than you could from a panel put together by Andrew Cuomo to look into workplace harassment or the NYPD to look into placard abuse,” he wrote in an open letter to an unnamed New York politician in 2022. He praised Alex Berenson, the former Times reporter whom Tucker Carlson referred to as his favorite “COVID contrarian.” He linked to a Joe Rogan episode featuring a vaccine scientist accused of spreading COVID disinformation. Much like Kennedy himself, he referred to the U.S. response to the pandemic as a “medical genocide” and a “state-sponsored crime” protected by “a massive cover up and disinformation campaign.”

    Like many of his supporters, Gorton sees Kennedy as a way out of this cycle of public-health failure and political corruption: the ostracized insider railing against the Establishment he grew up in. “The corruption is marbled into the very structure of the entire system,” Gorton says, referencing Kennedy’s books The Real Anthony Fauci and The Wuhan Cover-up. “You can see he has an encyclopedic knowledge of this corruption and how the system works.”

    Correction: A previous version of this article misstated the name of RFK Jr.’s nonprofit group.

    [ad_2]

    Matt Stieb

    Source link

  • Flu Shots Need to Stop Fighting ‘Something That Doesn’t Exist’

    Flu Shots Need to Stop Fighting ‘Something That Doesn’t Exist’

    [ad_1]

    Listen to this article

    Produced by ElevenLabs and NOA, News Over Audio, using AI narration.

    In Arnold Monto’s ideal vision of this fall, the United States’ flu vaccines would be slated for some serious change—booting a major ingredient that they’ve consistently included since 2013. The component isn’t dangerous. And it made sense to use before. But to include it again now, Monto, an epidemiologist and a flu expert at the University of Michigan, told me, would mean vaccinating people “against something that doesn’t exist.”

    That probably nonexistent something is Yamagata, a lineage of influenza B viruses that hasn’t been spotted by global surveyors since March of 2020, shortly after COVID mitigations plummeted flu transmission to record lows. “And it isn’t for lack of looking,” Kanta Subbarao, the director of the WHO’s Collaborating Centre for Reference and Research on Influenza, told me. In a last-ditch attempt to find the missing pathogen, a worldwide network of monitoring centers tested nearly 16,000 influenza B virus samples collected from February to August of last year. Not a single one of them came up Yamagata. “The consensus is that it’s gone,” Cheryl Cohen, the head of South Africa’s Centre for Respiratory Diseases and Meningitis, told me. Officially removing an ingredient from flu vaccines will codify that sentiment, effectively publishing Yamagata’s obituary.

    Last year around this time, Subbarao told me, the WHO was already gently suggesting that the world might want to drop Yamagata from vaccines; by September, the agency had grown insistent, describing the ingredient as “no longer warranted” and urging that “every effort should be made to exclude it as soon as possible.” The following month, an advisory committee to the FDA unanimously voted to speedily adopt that same change.

    But the switch from a four-flu vaccine to a trivalent one, guarding against only three, isn’t as simple as ordering the usual, please, just hold the Yams. Trivalent vaccines require their own licensure, which some manufacturers may have allowed to lapse—or never had at all; manufacturers must also adhere to the regulatory pipelines specific to each country. “People think, ‘They change the strains every season; this should be no big deal,’” Paula Barbosa, the associate director of vaccine policy at the International Federation of Pharmaceutical Manufacturers and Associations, which represents vaccine manufacturers, told me. This situation is not so simple: “They need to change their whole manufacturing process.” At the FDA advisory-committee meeting in October, an industry representative cautioned that companies might need until the 2025–26 season to fully transition to trivalents in the Northern Hemisphere, a timeline that Barbosa, too, considers realistic. The South could take until 2026.

    In the U.S., though, where experts such as Monto have been pushing for expedient change, a Yamagata-less flu vaccine could be coming this fall. When I reached out to CSL Seqirus and GSK, two of the world’s major flu-vaccine producers, a spokesperson from each company told me that their firm was on track to deliver trivalent vaccines to the U.S. in time for the 2024–25 flu season, should the relevant agencies recommend and request it. (The WHO’s annual meeting to recommend the composition of the Northern Hemisphere’s flu vaccine isn’t scheduled until the end of February; an FDA advisory meeting on the same topic will follow shortly after.) Sanofi, another vaccine producer, was less definitive, but told me that, with sufficient notice from health authorities, its plans would allow for trivalent vaccines this year, “if there is a definitive switch.” AstraZeneca, which makes the FluMist nasal-spray vaccine, told me that it was “engaging with the appropriate regulatory bodies” to coordinate the shift to a trivalent vaccine “as soon as possible.”

    Quadrivalent flu vaccines are relatively new. Just over a decade ago, the world relied on immunizations that included two flu A strains (H1N1 and H3N2), plus one B: either Victoria or Yamagata, whichever scientists predicted might be the bigger scourge in the coming flu season. “Sometimes the world got it wrong,” Mark Jit, an epidemiologist at the London School of Hygiene & Tropical Medicine, told me. To hedge their bets, experts eventually began to recommend simply sticking in both. But quadrivalent vaccines typically cost more to manufacture, experts told me. And although several countries, including the U.S., quickly transitioned to the heftier shots, many nations—especially those with fewer resources—never did.

    Now “the extra component is a waste,” Vijay Dhanasekaran, a virologist at the University of Hong Kong, told me. It’s pointless to ask people’s bodies to mount a defense against an enemy that will never attack. Trimming Yamagata out of flu-vaccine recipes should also make them cheaper, Dhanasekaran said, which could improve global access. Plus, continuing to manufacture Yamagata-focused vaccines raises the small but serious risk that the lineage could be inadvertently reintroduced to the world, Subbarao told me, as companies grow gobs of the virus for their production pipeline. (Some vaccines, such as FluMist, also immunize people with live-but-weakened versions of flu viruses.)

    Some of the researchers I spoke with for this article weren’t ready to rule out the possibility—however slim—that Yamagata is still biding its time somewhere. (Victoria, a close cousin of Yamagata, and the other B lineage that pesters people, once went mostly quiet for about a decade, before roaring back in the early aughts.) But most experts, at this point, are quite convinced. The past couple of flu seasons have been heavy enough to offer even a rather rare lineage the chance to reappear. “If it had been circulating in any community, I’m pretty sure that global influenza surveillance would have detected it by now,” Dhanasekaran said. Plus, even before the pandemic began, Yamagata had been the wimpiest of the flu bunch, Jit told me: slow to evolve, crummy at transmitting, and already dipping in prevalence. When responses to the pandemic starved all flu viruses of hosts, he said, this lineage was the likeliest to be lost.

    Eventually, companies may return to including four types of flu in their products, swapping in, say, another strain of H3N2, the most severe and fastest-evolving of the bunch—a change that Subbarao and Monto both told me might actually be preferable. But incorporating a second H3N2 is even more of a headache than returning to a trivalent vaccine: Researchers would likely first need to run clinical trials, experts told me, to ensure that the new components played nicely with each other and conferred additional benefits.

    For the moment, a slimmed-down vaccine is the quickest way to keep up with the flu’s current antics. And in doing so, those vaccines will also reflect the strange reality of this new, COVID-modified world. “A whole lineage of flu has probably been eliminated through changes in human behavior,” Jit told me. Humanity may not have intended it. But our actions against one virus may have forever altered the course of another.

    [ad_2]

    Katherine J. Wu

    Source link

  • Deer Are Beta-Testing a Nightmare Disease

    Deer Are Beta-Testing a Nightmare Disease

    [ad_1]

    Scott Napper, a biochemist and vaccinologist at the University of Saskatchewan, can easily envision humanity’s ultimate doomsday disease. The scourge would spread fast, but the progression of illness would be slow and subtle. With no immunity, treatments, or vaccines to halt its progress, the disease would eventually find just about every single one of us, spreading via all manner of body fluids. In time, it would kill everyone it infected. Even our food and drink would not be safe, because the infectious agent would be hardy enough to survive common disinfectants and the heat of cooking; it would be pervasive enough to infest our livestock and our crops. “Imagine if consuming a plant could cause a fatal, untreatable neurodegenerative disorder,” Napper told me. “Any food grown within North America would be potentially deadly to humans.”

    This nightmare illness doesn’t yet exist. But for inspiration, Napper needs to look only at the very real contagion in his own lab: chronic wasting disease (CWD), a highly lethal, highly contagious neurodegenerative disease that is devastating North America’s deer, elk, and other cervids.

    In the half century since it was discovered in a captive deer colony in Colorado, CWD has worked its way into more than 30 U.S. states and four Canadian provinces, as well as South Korea and several countries in Europe. In some captive herds, the disease has been detected in more than 90 percent of individuals; in the wild, Debbie McKenzie, a biologist at the University of Alberta, told me, “we have areas now where more than 50 percent of the bucks are infected.” And CWD kills indiscriminately, gnawing away at deer’s brains until the tissue is riddled with holes. “The disease is out of control,” Dalia Abdelaziz, a biochemist at the University of Calgary, told me.

    What makes CWD so formidable is its cause: infectious misfolded proteins called prions. Prion diseases, which include mad cow disease, have long been known as terrifying and poorly understood threats. And CWD is, in many ways, “the most difficult” among them to contend with—more transmissible and widespread than any other known, Marcelo Jorge, a wildlife biologist at the University of Georgia, told me. Scientists are quite certain that CWD will be impossible to eradicate; even limiting its damage will be a challenge, especially if it spills into other species, which could include us. CWD is already a perfect example of how dangerous a prion disease can be. And it has not yet hit the ceiling of its destructive potential.


    Among the world’s known infectious agents, prions are an anomaly, more like zombies than living entities. Unlike standard-issue microbes—viruses, bacteria, parasites, fungi—prions are just improperly folded proteins, devoid of genetic material, unable to build more of themselves from scratch, or cleave themselves in two. To reproduce, they simply find properly formed proteins that share their base composition and convert those to their aberrant shape, through mostly mysterious means. And because prions are slightly malformed versions of molecules that our bodies naturally make, they’re difficult to defend against. The immune system codes them as benign and ignores them, even as disease rapidly unfolds. “This is an entirely new paradigm of infectious disease,” Napper told me. “It’s a part of your own body that’s turning against you.”

    And yet, we’ve managed to keep many prion diseases in check. Kuru, once common in the highlands of Papua New Guinea, was transmitted through local rituals of funerary cannibalism; the disease fizzled out after people stopped those practices. Mad cow disease (more formally known as bovine spongiform encephalopathy) was contained by culling infected animals and eliminating the suspected source, cow feed made with infected tissues. Even scrapie, a highly contagious prion disease of sheep and goats, is limited to livestock, making it feasible to pare down infected populations, or breed them toward genetic resistance.

    CWD, meanwhile, is a fixture of wild animals, many of them migratory. And whereas most other prion diseases primarily keep quarters in the central nervous system, CWD “gets in pretty much every part of the body,” Jorge told me. Deer then pass on the molecules, often through direct contact; they’ll shed prions in their saliva, urine, feces, reproductive fluids, and even antler velvet long before they start to show symptoms. Candace Mathiason, a pathobiologist at Colorado State University, and her colleagues have found that as little as 100 nanograms of saliva can seed an infection. Her studies suggest that deer can also pass prions in utero from doe to growing fawn.

    Deer also ingest prions from their environment, where the molecules can linger in soil, on trees, and on hunting bait for years or decades. A team led by Sandra Pritzkow, a biochemist at UTHealth Houston, has found that plants can take up prions from the soil, too. And unlike the multitude of microbes that are easily done in by UV, alcohol, heat, or low humidity, prions are so structurally sound that they can survive nearly any standard environmental assault. In laboratories, scientists must blast their equipment with temperatures of about 275 degrees Fahrenheit for 60 to 90 minutes, under extreme pressure, to rid it of prions—or drench their workspaces with bleach or sodium hydroxide, at concentrations high enough to rapidly corrode flesh.

    Infected deer are also frustratingly difficult to detect. The disease typically takes years to fully manifest, while the prions infiltrate the brain and steadily destroy neural tissue. The molecules kill insidiously: “This isn’t the kind of disease where you might get a group of deer that are all dead around this watering hole,” Jorge told me. Deer drift away from the herd; they forage at odd times. They become braver around us. They drool and urinate more, stumble about, and begin to lose weight. Eventually, a predator picks them off, or a cold snap freezes them, or they simply starve; in all cases, though, the disease is fatal. Because of CWD, deer populations in many parts of North America are declining; “there is definitely some concern that local populations will disappear,” McKenzie told me. Researchers worry the disease will soon overwhelm caribou in Canada, imperiling the Indigenous communities who rely on them for food. Hunters and farmers, too, are losing vital income. Deer are unlikely to go extinct, but the disease is depriving their habitats of key grazers, and their predators of food.

    In laboratory experiments, CWD has proved capable of infecting rodents, sheep, goats, cattle, raccoons, ferrets, and primates. But so far, jumps into non-cervid species don’t seem to be happening in the wild—and although people eat an estimated 10,000 CWD-infected cervids each year, no human cases have been documented. Still, lab experiments indicate that human proteins, at least when expressed by mice, could be susceptible to CWD too, Sabine Gilch, a molecular biologist at the University of Calgary, told me.

    And the more prions transmit, and the more hosts they find themselves in, the more opportunities they may have to infect creatures in new ways. Prions don’t seem to evolve as quickly as many viruses or bacteria, Gilch told me. But “they’re not as static as we would like them to be.” She, McKenzie, and other researchers have detected a multitude of CWD strains bopping around in the wild—each with its own propensity for interspecies spread. With transmission so unchecked, and hosts so numerous, “this is kind of like a ticking time bomb,” Surachai Suppattapone, a biochemist at Dartmouth, told me.


    The world is unlikely to ever be fully rid of CWD; even the options to slow its advance are so far limited. Efforts to survey for infection depend on funding and researchers’ time, or the generosity of local hunters for samples; environmental decontamination is still largely experimental and tricky to do at scale; treatments—which don’t yet exist—would be nearly impossible to administer en masse. And culling campaigns, although sometimes quite effective, especially at the edges of the disease’s reach, often spark public backlash.

    Deer that carry certain genetic variants do seem less susceptible to prions, and progress more slowly to full-blown disease and death. But because none so far seems able to fully block infection, or completely curb shedding, prolonging life may simply prolong transmission. “Once an animal gets infected,” Abdelaziz told me, there’s almost a “hope it dies right away.” Even if sturdier prion resistance is someday found, “it’s probably just a matter of time until prions start to adapt to that as well,” Gilch said.

    Vaccines, in theory, could help, and in recent years, several research groups—including Napper’s and Abdelaziz’s—have made breakthroughs in overcoming the immune system’s inertia in attacking proteins that look like the body’s own. Some strategies try to target the problematic, invasive prions only; others are going after both the prion and the native, properly folded protein, so that the vaccine can do double duty, waylaying the infectious invader and starving it of reproductive fodder. (So far, lab animals seem to do mostly fine even when they’re bred to lack the native prion protein, whose function is still mostly mysterious.) In early trials, both teams’ vaccines have produced promising immune responses in cervids. But neither team yet fully knows how effective their vaccines are at cutting down on shedding, how long that protection might last, or whether these strategies will work across cervid species. One of Napper’s vaccine candidates, for instance, seemed to hasten the progression of disease in elk.

    Vaccines for wildlife are also tough to deliver, especially the multiple doses likely needed in this case. “It’s not like you can just run around injecting every elk and deer,” Napper told me. Instead, he and other researchers plan to compound their formula with a salty apple-cider slurry that he hopes wild cervids might eat with some regularity. “The deer absolutely love it,” he said.

    Should any CWD vaccines come to market, though, they will almost certainly be the first prion vaccines that clear the experimental stage. That could be a boon for more than just deer. Another prion disease may spill over from one species to another; others may arise spontaneously. CWD is not, and may never be, the prion disease that most directly affects us. But it is, for now, the most urgent—and the one from which we have the most to lose, and maybe gain.

    [ad_2]

    Katherine J. Wu

    Source link

  • SingleTimeMicroneedles, Inc. Selected as Finalist for 2024 SXSW Pitch

    SingleTimeMicroneedles, Inc. Selected as Finalist for 2024 SXSW Pitch

    [ad_1]

    SingleTimeMicroneedles to showcase STM Patch in the Food, Nutrition, and Health category

    SingleTimeMicroneedes, Inc., a microneedle drug development and delivery company has been selected as a finalist in the Food, Nutrition, and Health category for the 15th annual SXSW Pitch (formerly SXSW Accelerator). 

    SXSW Pitch, presented by KPMG, is the marquee event of South by Southwest® (SXSW®) Conference & Festivals (March 8 – 16, 2024), where leading startups from around the world showcase some of the most impressive technology innovations to a panel of hand-picked judges and a live audience. Out of the 670 companies that applied to present at SXSW Pitch 2024, STM was selected among the 45 finalists spanning nine separate categories.

    SingleTimeMicroneedles has developed a drug and vaccine microneedle delivery platform that can revolutionize access to lifesaving pharma products in animals and humans. The microneedle patch temperature stabilizes drugs and vaccines to eliminate the need for cold-chain storage and transportation and are the only patches that can deliver doses immediately, over-time, or separately over weeks/months in one application. The technology supports most types of vaccines and therapeutics, including large molecules, subunit protein-based antigens, vector-based vaccines, mRNAs, and any compound that benefits from multiple/longitudinal dosing. STM patches have broad applications and are being planned for use in animals and humans.

    “We believe that our technology will have a huge impact on the health of humans, animals, and whole communities by democratizing access to critical drugs and vaccines and are honored to have the opportunity afforded by SXSW to share our product and mission,” said CEO and co-founder, Jasdeep Singh.

    The initial technology for SingleTimeMicroneedles came out Dr. Thanh Nguyen’s lab at the University of Connecticut. Dr. Nguyen said, “Translating a research product from the lab to the market is always my goal and I think SingleTimeMicroneedles will make a large impact in healthcare and add to the research.”

    The two-day SXSW Pitch event will be held the first weekend of the SXSW Conference & Festivals, Saturday, March 9 and Sunday, March 10, on the fourth floor of the Downtown Hilton Austin, Salon D/E. The event will then culminate with the 2024 SXSW Pitch Awards Ceremony on Sunday evening, March 10, where winning startups from each category and a Best in Show winner will be announced and honored in Salon H on the sixth floor of the Hilton Hotel.

    Source: SingleTimeMicroneedles, Inc.

    [ad_2]

    Source link

  • Cameroon Starts World-First Malaria Vaccine Program for Kids

    Cameroon Starts World-First Malaria Vaccine Program for Kids

    [ad_1]

    Cameroon will be the first country to routinely give children a new malaria vaccine as the shots are rolled out in Africa.

    The campaign due to start Monday was described by officials as a milestone in the decades-long effort to curb the mosquito-spread disease on the continent, which accounts for 95% of the world’s malaria deaths.

    “The vaccination will save lives. It will provide major relief to families and the country’s health system,” said Aurelia Nguyen, chief program officer at the Gavi vaccines alliance, which is helping Cameroon secure the shots.

    The Central Africa nation hopes to vaccinate about 250,000 children this year and next year. Gavi said it is working with 20 other African countries to help them get the vaccine and that those countries will hopefully immunize more than 6 million children through 2025.

    In Africa, there are about 250 million cases of the parasitic disease each year, including 600,000 deaths, mostly in young children.

    Cameroon will use the first of two recently approved malaria vaccines, known as Mosquirix. The World Health Organization endorsed the vaccine two years ago, acknowledging that that even though it is imperfect, its use would still dramatically reduce severe infections and hospitalizations.

    The GlaxoSmithKline-produced shot is only about 30% effective, requires four doses and protection begins to fade after several months. The vaccine was tested in Africa and used in pilot programs in three countries.

    GSK has said it can only produce about 15 million doses of Mosquirix a year and some experts believe a second malaria vaccine developed by Oxford University and approved by WHO in October might be a more practical solution. That vaccine is cheaper, requires three doses and India’s Serum Institute said they could make up to 200 million doses a year.

    Gavi’s Nguyen said they hoped there might be enough of the Oxford vaccines available to begin immunizing people later this year.

    Neither of the malaria vaccines stop transmission, so other tools like bed nets and insecticidal spraying will still be critical. The malaria parasite mostly spreads to people via infected mosquitoes and can cause symptoms including fever, headaches and chills.

    [ad_2]

    Associated Press

    Source link

  • How fringe anti-science views infiltrated mainstream politics — and what it means in 2024

    How fringe anti-science views infiltrated mainstream politics — and what it means in 2024

    [ad_1]

    Rates of routine childhood vaccination hit a 10-year low in 2023. That, according to the Centers for Disease Control and Prevention, puts about 250,000 kindergartners at risk for measles, which often leads to hospitalization and can cause death. In recent weeks, an infant and two young children have been hospitalized amid an ongoing measles outbreak in Philadelphia that spread to a day care center.

    It’s a dangerous shift driven by a critical mass of people who now reject decades of science backing the safety and effectiveness of childhood vaccines. State by state, they’ve persuaded legislators and courts to more easily allow children to enter kindergarten without vaccines, citing religious, spiritual, or philosophical beliefs.

    Growing vaccine hesitancy is just a small part of a broader rejection of scientific expertise that could have consequences ranging from disease outbreaks to reduced funding for research that leads to new treatments. “The term ‘infodemic’ implies random junk, but that’s wrong,” said Peter Hotez, a vaccine researcher at Baylor College of Medicine in Texas. “This is an organized political movement, and the health and science sectors don’t know what to do.”

    Changing views among Republicans have steered the relaxation of childhood vaccine requirements, according to the Pew Research Center. Whereas nearly 80% of Republicans supported the rules in 2019, fewer than 60% do today. Democrats have held steady, with about 85% supporting. Mississippi, which once boasted the nation’s highest rates of childhood vaccination, began allowing religious exemptions last summer. Another leader in vaccination, West Virginia, is moving to do the same.

    An anti-science movement picked up pace as Republican and Democratic perspectives on science diverged during the pandemic. Whereas 70% of Republicans said that science has a mostly positive impact on society in 2019, less than half felt that way in a November poll from Pew. With presidential candidates lending airtime to anti-vaccine messages and members of Congress maligning scientists and pandemic-era public health policies, the partisan rift will likely widen in the run-up to November’s elections.

    Dorit Reiss, a vaccine policy researcher at the University of California Law San Francisco, draws parallels between today’s backlash against public health and the early days of climate change denial. Both issues progressed from nonpartisan, fringe movements to the mainstream once they appealed to conservatives and libertarians, who traditionally seek to limit government regulation. “Even if people weren’t anti-vaccine to start with,” Reiss said, “they move that way when the argument fits.”

    Even certain actors are the same. In the late ’90s and early 2000s, a libertarian think tank, the American Institute for Economic Research, undermined climate scientists with reports that questioned global warming. The same institute issued a statement early in the pandemic, grandly called the “Great Barrington Declaration.” It argued against measures to curb the disease and advised everyone — except the most vulnerable — to go about their lives as usual, regardless of the risk of infection. Tedros Adhanom Ghebreyesus, director-general of the World Health Organization, warned that such an approach would overwhelm health systems and put millions more at risk of disability and death from COVID. “Allowing a dangerous virus that we don’t fully understand to run free is simply unethical,” he said.

    Another group, the National Federation of Independent Business, has fought regulatory measures to curb climate change for over a decade. It moved on to vaccines in 2022 when it won a Supreme Court case that overturned a government effort to temporarily require employers to mandate that workers either be vaccinated against COVID or wear a face mask and test on a regular basis. Around 1,000 to 3,000 COVID deaths would have been averted in 2022 had the court upheld the rule, one study estimates.

    Politically charged pushback may become better funded and more organized if public health becomes a political flashpoint in the lead-up to the presidential election. In the first few days of 2024, Florida’s surgeon general, appointed by Republican presidential candidate and Florida Gov. Ron DeSantis, called for a halt to use of mRNA COVID vaccines as he echoed DeSantis’ incorrect statement that the shots have “not been proven to be safe and effective.” And vaccine skeptic Robert F. Kennedy Jr., who is running for president as an independent, announced that his campaign communications would be led by Del Bigtree, the executive director of one of the most well-heeled anti-vaccine organizations in the nation and host of a conspiratorial talk show. Bigtree posted a letter on the day of the announcement rife with misinformation, such as a baseless rumor that COVID vaccines make people more prone to infection. He and Kennedy frequently pair health misinformation with terms that appeal to anti-government ideologies like “medical freedom” and “religious freedom.”

    A product of a Democratic dynasty, Kennedy’s appeal appears to be stronger among Republicans, a Politico analysis found. DeSantis said he would consider nominating Kennedy to run the FDA, which approves drugs and vaccines, or the CDC, which advises on vaccines and other public health measures. Another Republican candidate for president, Vivek Ramaswamy, vowed to gut the CDC should he win.

    Robert Kennedy Jr Begins Presidential Campaign In Miami
    Independent presidential candidate Robert F. Kennedy Jr. speaks during a campaign event in Miami on Oct. 12, 2023.

    / Getty Images


    Today’s anti-science movement found its footing in the months before the 2020 elections, as primarily Republican politicians rallied support from constituents who resented pandemic measures like masking and the closure of businesses, churches, and schools. Then-President Donald Trump, for example, mocked Joe Biden for wearing a mask at the presidential debate in September 2020. Democrats fueled the politicization of public health, too, by blaming Republican leaders for the country’s soaring death rates, rather than decrying systemic issues that rendered the U.S. vulnerable, such as underfunded health departments and severe economic inequality that put some groups at far higher risk than others. Just before Election Day, a Democratic-led congressional subcommittee released a report that called the Trump administration’s pandemic response “among the worst failures of leadership in American history.”

    After Biden took office, Republican lawmakers who had encouraged COVID vaccination began to pivot, questioning the safety of the vaccines and introducing dozens of bills to block vaccine mandates. House Republicans launched a subcommittee investigation into the pandemic that sharply criticizes scientific institutions and scientists once seen as nonpartisan. On Jan. 8 and 9, the group questioned Anthony Fauci, a leading infectious disease researcher who has advised both Republican and Democratic presidents. Without evidence, committee member Marjorie Taylor Greene (R-Ga.) accused Fauci of supporting research that created the coronavirus in order to push vaccines: “He belongs in jail for that,” Greene, a vaccine skeptic, said. “This is like a, more of an evil version of science.”

    Taking a cue from environmental advocacy groups that have tried to fight strategic and monied efforts to block energy regulations, Hotez and other researchers say public health needs supporters knowledgeable in legal and political arenas. Such groups might combat policies that limit public health power, advise lawmakers, and provide legal counsel to scientists who are harassed or called before Congress in politically charged hearings. Other initiatives aim to present the scientific consensus clearly to avoid both-sidesism, in which the media presents opposing viewpoints as equal when, in fact, the majority of researchers and bulk of evidence point in one direction. Oil and tobacco companies used this tactic effectively to seed doubt about the science linking their industries to harm.

    Kathleen Hall Jamieson, director of the Annenberg Public Policy Center at the University of Pennsylvania, said the scientific community must improve its communication. Expertise, alone, is insufficient when people mistrust the experts’ motives. Indeed, nearly 40% of Republicans report little to no confidence in scientists to act in the public’s best interest.

    In a study published last year, Jamieson and colleagues identified attributes the public values beyond expertise, including transparency about unknowns and self-correction. Researchers might have better managed expectations around COVID vaccines, for example, by emphasizing that the protection conferred by most vaccines is less than 100% and wanes over time, requiring additional shots, Jamieson said. And when the initial COVID vaccine trials demonstrated that the shots drastically curbed hospitalization and death but revealed little about infections, public health officials might have been more open about their uncertainty.

    As a result, many people felt betrayed when COVID vaccines only moderately reduced the risk of infection. “We were promised that the vaccine would stop transmission, only to find out that wasn’t completely true, and America noticed,” said Rep. Brad Wenstrup (R-Ohio), chair of the Republican-led coronavirus subcommittee, at a July hearing.

    Jamieson also advises repetition. It’s a technique expertly deployed by those who promote misinformation, which perhaps explains why the number of people who believe the anti-parasitic drug ivermectin treats COVID more than doubled over the past two years — despite persistent evidence to the contrary. In November, the drug got another shoutout at a hearing where congressional Republicans alleged that the Biden administration and science agencies had censored public health information.

    Hotez, author of a new book on the rise of the anti-science movement, fears the worst. “Mistrust in science is going to accelerate,” he said.

    And traditional efforts to combat misinformation, such as debunking, may prove ineffective.

    “It’s very problematic,” Jamieson said, “when the sources we turn to for corrective knowledge have been discredited.”


    KFF Health News, formerly known as Kaiser Health News (KHN), is a national newsroom that produces in-depth journalism about health issues and is one of the core operating programs at KFF — the independent source for health policy research, polling, and journalism.

    [ad_2]

    Source link

  • The New Vaccines to Get in 2024

    The New Vaccines to Get in 2024

    [ad_1]

    The U.S. Centers for Disease Control and Prevention (CDC) is recommending new vaccines for adults and kids in 2024, according to its latest annual guidelines finalized Jan. 11. The CDC’s Advisory Committee on Immunization Practices (ACIP), a collection of medical and public-health experts who regularly review evidence and research about vaccines, compiled the new guidelines.

    Like it does every year, ACIP recommends that American adults receive an annual flu shot and several standard vaccinations, such as those for chickenpox (if they haven’t had it already) and tetanus. For infants and children, the pediatric immunization plan that includes shots such as the measles, mumps, and rubella (MMR) vaccine remains mostly the same.

    However, the 2024 schedule has some notable changes. Here are the vaccines newly recommended for Americans. 

    The latest COVID-19 vaccine (for kids and adults)

    All adults and children 6 months or older should receive a dose of an updated COVID-19 vaccine in 2024, ACIP says. The most current shot targets the Omicron variant XBB.15, replacing the bivalent mRNA booster previously recommended on the vaccination schedule. This updated vaccine protects against evolving strains including the JN.1 variant surging in the U.S.

    The recommendations come amid historic lows for vaccine uptake in the U.S., leading to outbreaks of dangerous diseases like measles in pockets of the country. Anti-vaccine sentiment is on the rise.

    Low COVID-19 vaccination rates are a particularly concerning issue. So far, fewer than 20% of adults in the U.S.—and just 8% of eligible kids—have gotten the shot. The updated COVID-19 vaccine is highly protective against hospitalization, serious illness, and death. People vaccinated before contracting COVID-19 are also four times less likely to develop Long COVID, though we now know that the risk also goes up with repeat infections.

    Read More: The Updated COVID-19 Shot Works on the Newest Variants

    Missing from the document is a plan for increasing vaccine uptake. In a new editorial published in the journal Annals of Internal Medicine, a group of physicians from City University of New York (CUNY) argue that the absence of any sort of uptake strategy within the CDC’s annual document feels like a glaring omission so many years into the pandemic. It “demonstrates that CDC has not moved sufficiently beyond merely providing information to clinicians and the public to persuasive communication,” the CUNY group writes. 

    Mpox vaccine (for some adults)

    2024 is the first time the government is formally recommending the mpox vaccine on an annual schedule for those in high-risk groups, which includes certain members of the LGBTQ community who may have been exposed to the virus formerly called monkeypox. Mpox cases in the U.S. have remained low since peaking in August 2022, with fewer than 10 new cases per day on average, but the CDC stresses that the two-dose vaccination plays an important role in keeping case numbers down. Those who have already received two doses of the mpox vaccine do not need further vaccination at this time, the agency says.

    Respiratory syncytial virus (RSV) shot (for some kids and adults)

    Pfizer’s new RSV vaccine, Abrysvo, received U.S. Food and Drug Administration (FDA) approval in May 2023. The CDC recommends it for two groups: people who are nearing the end of a pregnancy during RSV season (between September and January), and anyone over age 60. Seniors also have the option of taking a different new RSV vaccine made by GlaxoSmithKline called Arexvy. Pfizer is currently testing Abrysvo in children ages 2 to 17 at high risk for RSV.

    A different RSV shot is also newly recommended for infants up to eight months old if their mothers did not receive an RSV vaccine during pregnancy. The monoclonal antibody nirsevimab—brand name: Beyfortus—was approved by the FDA in July 2023, and recent studies have shown that it’s effective at keeping kids out of the hospital.

    A combination meningitis vaccine (for some kids and adults)

    Pfizer’s new vaccine Penbraya, which was approved by the FDA in October, protects against the five most common variations of meningococcal disease affecting adolescents and young adults globally. 2024 marks its first appearance on the vaccination schedules for some children and adults; doctors are now being asked to consider it as an alternative for patients 10 years and older who would otherwise receive the two meningitis vaccines currently in use, which cover the same five variations together. Penbraya is given as two doses six months apart.

    [ad_2]

    Haley Weiss

    Source link

  • Rising flu, COVID, RSV rates: Johns Hopkins expert available for interviews

    Rising flu, COVID, RSV rates: Johns Hopkins expert available for interviews

    [ad_1]

    Andrew Pekosz, PhD, professor and vice chair in the Department of Molecular Microbiology and Immunology at the Johns Hopkins Bloomberg School of Public Health, is available for media interviews to discuss the rising rates of respiratory illnesses, the declining rate of vaccinations, and the Centers for Disease Control and Prevention’s Health Advisory urging healthcare providers to encourage their patients to get vaccinated. 

    Journalists are also welcome to use the following comment from Andrew Pekosz:  

    “It’s troubling that we’re seeing increased hospitalizations from influenza and COVID-19 at the same time that vaccination rates are falling. It is critical that people stay up-to-date on their vaccinations, and that is particularly true for individuals in high-risk groups, to mitigate the chances of illness or even death.” 

    The CDC reported that in the past month, “hospitalizations among all age groups increased by 200% for influenza, 51% for COVID-19, and 60% for RSV. As of December 1, 2023, the weekly percentages of pediatric emergency department visits for pneumonia due to multiple etiologies were increasing since September in children, but remains consistent with prior fall and winter respiratory activity. To date, 12 pediatric influenza deaths have been reported during the 2023–2024 season. From September 1 through December 10, 2023, CDC received 30 reports of MIS-C, a rare complication that typically occurs 1 month after SARS-CoV-2 infection, with illness onset among cases occurring from August 6 to November 9, 2023, a relative increase compared with previous months. High RSV activity is also occurring across much of the United States.”

    The CDC also stated that “as of November 18, 2023, there were 7.4 million fewer influenza vaccine doses administered to adults in pharmacies and physician offices compared with the 2022–2023 influenza season” and that “as of December 2, 2023, the percent of the population reporting receipt of [the COVID-19] vaccine was 7.7% in children 6 months–17 years (including 2.8% in children 6 months–4 years), 17.2% in adults ≥18 years (including 36% in adults ≥65 years), and 9.6% in pregnant persons. … As of December 2, 2023, 15.9% of U.S. adults aged ≥60 years reported receiving an RSV vaccine.” 

    # # #

    [ad_2]

    Johns Hopkins Bloomberg School of Public Health

    Source link

  • ‘Long flu’ has emerged as a consequence similar to long COVID

    ‘Long flu’ has emerged as a consequence similar to long COVID

    [ad_1]

    BYLINE: Kristina Sauerwein

    Newswise — Since the COVID-19 pandemic began, extensive research has emerged detailing the virus’s ability to attack multiple organ systems, potentially resulting in a set of enduring and often disabling health problems known as long COVID. Now, new research from Washington University School of Medicine in St. Louis and the Veterans Affairs St. Louis Health Care System indicates that people hospitalized with seasonal influenza also can suffer long-term, negative health effects, especially involving their lungs and airways.

    The new study comparing the viruses that cause COVID-19 and the flu also revealed that in the 18 months after infection, patients hospitalized for either COVID-19 or seasonal influenza faced an increased risk of death, hospital readmission, and health problems in many organ systems. Further, the time of highest risk was 30 days or later after initial infection.

    “The study illustrates the high toll of death and loss of health following hospitalization with either COVID-19 or seasonal influenza,” said senior author Ziyad Al-Aly, MD, a clinical epidemiologist at Washington University. “It’s critical to note that the health risks were higher after the first 30 days of infection. Many people think they’re over COVID-19 or the flu after being discharged from the hospital. That may be true for some people. But our research shows that both viruses can cause long-haul illness.”

    The findings are published Dec. 14 in The Lancet Infectious Diseases.

    The statistical analysis spanned up to 18 months post-infection and included a comparative evaluation of risks of death, hospital admissions and 94 adverse health outcomes involving the body’s major organ systems.

    “A review of past studies on COVID-19 versus the flu focused on a short-term and narrow set of health outcomes,” said Al-Aly, who treats patients within the VA St. Louis Health Care System and is an assistant professor of medicine at Washington University. “Our novel approach compared the long-term health effects of a vast array of conditions. Five years ago, it wouldn’t have occurred to me to examine the possibility of a ‘long flu.’ A major lesson we learned from SARS-CoV-2 is that an infection that initially was thought to only cause brief illness also can lead to chronic disease. This revelation motivated us to look at long-term outcomes of COVID-19 versus flu.

    “We wanted to know whether and to what degree people with flu also experience long-term health effects,” Al-Aly said. “The big answer is that both COVID-19 and the flu led to long-term health problems, and the big aha moment was the realization that the magnitude of long-term health loss eclipsed the problems that these patients endured in the early phase of the infection. Long COVID is much more of a health problem than COVID, and long flu is much more of a health problem than the flu.”

    However, the overall risk and occurrence of death, hospital admissions, and loss of health in many organ systems are substantially higher among COVID-19 patients than among those who have had seasonal influenza, Al-Aly said. “The one notable exception is that the flu poses higher risks to the pulmonary system than COVID-19,” he said. “This tells us the flu is truly more of a respiratory virus, like we’ve all thought for the past 100 years. By comparison, COVID-19 is more aggressive and indiscriminate in that it can attack the pulmonary system, but it can also strike any organ system and is more likely to cause fatal or severe conditions involving the heart, brain, kidneys and other organs.”

    The researchers analyzed de-identified medical records in a database maintained by the U.S. Department of Veterans Affairs, the nation’s largest integrated health-care delivery system. They evaluated information involving 81,280 patients hospitalized for COVID-19 at some point from March 1, 2020, through June 30, 2022, as well as 10,985 patients hospitalized for seasonal influenza at some point from Oct. 1, 2015, through Feb. 28, 2019.

    Patients represented multiple ages, races and sexes.

    Regarding both viruses, patient vaccination status did not affect results. Those in the COVID-19 cohort were hospitalized during the pre-delta, delta and omicron eras.

    During the overall 18-month study period, patients who had COVID-19 faced a 50% higher risk of death than those with seasonal influenza. This corresponded to about eight more deaths per 100 persons in the COVID-19 group than among those with the flu.

    Although COVID-19 showed a greater risk of health loss than seasonal influenza, infection with either virus carried significant risk of disability and disease. The researchers found COVID-19 exhibited increased risk of 68% of health conditions examined across all organ systems (64 of the 94 adverse health outcomes studied), while the flu was associated with elevated risk of 6% of health conditions (six of the 94) – mostly in the respiratory system.

    Also, over 18 months, COVID-19 patients experienced an increased risk of hospital readmission as well as admission to an intensive care unit (ICU). For every 100 persons in each group, there were 20 more hospital admissions and nine more ICU admissions in COVID-19 than flu.

    “Our findings highlight the continued need to reduce the risk of hospitalization for these two viruses as a way to alleviate the overall burden of health loss in populations,” Al-Aly said. “For both COVID-19 and seasonal influenza, vaccinations can help prevent severe disease and reduce the risk of hospitalizations and death. Optimizing vaccination uptake must remain a priority for governments and health systems everywhere. This is especially important for vulnerable populations such as the elderly and people who are immunocompromised.”

    In both COVID-19 and the flu, more than half of death and disability occurred in the months after infection as opposed to the first 30 days, the latter of which is known as the acute phase.

    “The idea that COVID-19 or flu are just acute illnesses overlooks their larger long-term effects on human health,” Al-Aly said. “Before the pandemic, we tended to belittle most viral infections by regarding them as somewhat inconsequential: ‘You’ll get sick and get over it in a few days.’ But we’re discovering that is not everyone’s experience. Some people are ending up with serious long-term health issues. We need to wake up to this reality and stop trivializing viral infections and understand that they are major drivers of chronic diseases.”

    [ad_2]

    Washington University in St. Louis

    Source link

  • Needle-Free Ultrasound Vaccine Delivery #Acoustics23

    Needle-Free Ultrasound Vaccine Delivery #Acoustics23

    [ad_1]

    Newswise — SYDNEY, Dec. 4, 2023 – An estimated quarter of adults and two-thirds of children have strong fears around needles, according to the U.S. Centers for Disease Control and Prevention. Yet, public health depends on people being willing to receive vaccines, which are often administered by a jab.

    Darcy Dunn-Lawless, a doctoral student at the University of Oxford’s Institute of Biomedical Engineering, is investigating the potential of a painless, needle-free vaccine delivery by ultrasound. He will share the recent advancements in this promising technique as part of Acoustics 2023 Sydney, running Dec. 4-8 at the International Convention Centre Sydney. His presentation will take place Dec. 4 at 11:00 a.m. Australian Eastern Daylight Time.

    “Our method relies on an acoustic effect called ‘cavitation,’ which is the formation and popping of bubbles in response to a sound wave,” said Dunn-Lawless. “We aim to harness the concentrated bursts of mechanical energy produced by these bubble collapses in three main ways. First, to clear passages through the outer layer of dead skin cells and allow vaccine molecules to pass through. Second, to act as a pump that drives the drug molecules into these passages. Lastly, to open up the membranes surrounding the cells themselves, since some types of vaccine must get inside a cell to function.”

    Though initial in vivo tests reported 700 times fewer vaccine molecules were delivered by the cavitation approach compared to conventional injection, the cavitation approach produced a higher immune response. The researchers theorize this could be due to the immune-rich skin the ultrasonic delivery targets in contrast to the muscles that receive the jab. The result is a more efficient vaccine that could help reduce costs and increase efficacy with little risk of side effects.

    “In my opinion, the main potential side effect is universal to all physical techniques in medicine: If you apply too much energy to the body, you can damage tissue,” Dunn-Lawless said. “Exposure to excessive cavitation can cause mechanical damage to cells and structures. However, there is good evidence that such damage can be avoided by limiting exposure, so a key part of my research is to try and fully identify where this safety threshold lies for vaccine delivery.”

    Dunn-Lawless works as part of a larger team under the supervision of Dr. Mike Gray, Professor Bob Carlisle, and Professor Constantin Coussios within Oxford’s Biomedical Ultrasonics, Biotherapy and Biopharmaceuticals Laboratory (BUBBL). Their cavitation approach may be particularly conducing to DNA vaccines that are currently difficult to deliver. With cavitation able to help crack open the membranes blocking therapeutic access to the cell nucleus, the other advantages of DNA vaccines, like a focused immune response, low infection risk, and shelf stability, can be better utilized.

    ###

    ———————– MORE MEETING INFORMATION ———————–

    The Acoustical Society of America is joining with the Australian Acoustical Society to co-host Acoustics 2023 Sydney. This collaborative event will incorporate the Western Pacific Acoustics Conference and the Pacific Rim Underwater Acoustics Conference.

    Main meeting website: https://acoustics23sydney.org/ 
    Technical program: https://eppro01.ativ.me/src/EventPilot/php/express/web/planner.php?id=ASAFALL23     

    ASA PRESS ROOM

    In the coming weeks, ASA’s Press Room will be updated with newsworthy stories and the press conference schedule at https://acoustics.org/asa-press-room/

    LAY LANGUAGE PAPERS

    ASA will also share dozens of lay language papers about topics covered at the conference. Lay language papers are summaries (300-500 words) of presentations written by scientists for a general audience. They will be accompanied by photos, audio, and video. Learn more at https://acoustics.org/lay-language-papers/.

    PRESS REGISTRATION

    ASA will grant free registration to credentialed and professional freelance journalists. If you are a reporter and would like to attend the meeting or virtual press conferences, contact AIP Media Services at [email protected]. For urgent requests, AIP staff can also help with setting up interviews and obtaining images, sound clips, or background information.

    ABOUT THE ACOUSTICAL SOCIETY OF AMERICA

    The Acoustical Society of America (ASA) is the premier international scientific society in acoustics devoted to the science and technology of sound. Its 7,000 members worldwide represent a broad spectrum of the study of acoustics. ASA publications include The Journal of the Acoustical Society of America (the world’s leading journal on acoustics), JASA Express Letters, Proceedings of Meetings on Acoustics, Acoustics Today magazine, books, and standards on acoustics. The society also holds two major scientific meetings each year. See https://acousticalsociety.org/.

    ABOUT THE AUSTRALIAN ACOUSTICAL SOCIETY

    The Australian Acoustical Society (AAS) is the peak technical society for individuals working in acoustics in Australia. The AAS aims to promote and advance the science and practice of acoustics in all its branches to the wider community and provide support to acousticians. Its diverse membership is made up from academia, consultancies, industry, equipment manufacturers and retailers, and all levels of Government. The Society supports research and provides regular forums for those who practice or study acoustics across a wide range of fields The principal activities of the Society are technical meetings held by each State Division, annual conferences which are held by the State Divisions and the ASNZ in rotation, and publication of the journal Acoustics Australia. https://www.acoustics.org.au/ 

    ###

    [ad_2]

    Acoustical Society of America (ASA)

    Source link

  • Pfizer gets FDA green light for new shot that can streamline teenagers’ vaccinations

    Pfizer gets FDA green light for new shot that can streamline teenagers’ vaccinations

    [ad_1]

    Pfizer Inc.
    PFE,
    -1.73%

    said Friday that the U.S. Food and Drug Administration has approved the first five-in-one vaccine designed to protect teenagers and young adults against meningococcal disease. 

    The new Pfizer shot, Penbraya, protects against the five most common subgroups of meningococcal disease, a rare but serious and potentially fatal illness that most often affects babies and teenagers. 

    Penbraya “has the potential to protect more adolescents and young adults from this severe and unpredictable disease by providing the broadest meningococcal coverage in the fewest shots,” Annaliesa Anderson, Pfizer senior vice president and head of vaccine research and development, said in a statement. 

    The U.S. Centers for Disease Control and Prevention currently recommends that all 11- to 12-year-olds get a meningococcal vaccine protecting against four of the subgroups — A, C, W and Y — and get a booster dose of the same vaccine type at age 16. Teenagers and young adults age 16 to 23 may also get a meningococcal B vaccine, the CDC says, particularly if they’re at increased risk due to other health conditions. 

    The complex vaccination schedule has weighed on uptake of the meningococcal shots, and the COVID-19 pandemic may have compounded the problem, as many families missed routine appointments when vaccinations were due, researchers say. Among teenagers who were born in 2008 — who were due for their routine adolescent vaccinations as the pandemic was raging in 2020 — uptake of meningococcal and other recommended vaccines declined, according to CDC research. Only about 60% of the 17-year-olds surveyed by the CDC last year had received both recommended doses of the ACWY vaccine, and fewer than 30% had received at least one dose of the meningococcal B vaccine. 

    The new Pfizer shot combines components of a meningococcal group B vaccine and an ACWY vaccine. 

    A CDC immunization advisory committee is set to meet Oct. 25 to discuss recommendations for the use of Penbraya in teenagers and young adults, Pfizer said. 

    The green light for Penbraya gives Pfizer the edge in its race with GSK
    GSK,
    +0.54%
    ,
    which is also working on a five-in-one meningococcal shot. GSK earlier this year released positive late-stage clinical-trial results for that vaccine. 

    The FDA approval of Pfizer’s shot caps a rocky week for the pharmaceutical giant, which late last Friday cut $9 billion from its full-year revenue guidance due to reduced COVID sales expectations and announced a cost-cutting program designed to deliver savings of at least $3.5 billion. Pfizer executives said on a call with analysts Monday that development of combination respiratory vaccines, such as those that provide COVID and flu protection in one shot, remains a focus for the company, in part because they can help boost vaccine uptake.

    Pfizer shares were down 1.7% Friday and have dropped 40% in the year to date, while the S&P 500
    SPX
    has gained 10%.

    [ad_2]

    Source link

  • Johns Hopkins Study Supports Potential for Injectable ‘Chemical Vaccine’ For Malaria Using Atovaquone

    Johns Hopkins Study Supports Potential for Injectable ‘Chemical Vaccine’ For Malaria Using Atovaquone

    [ad_1]

    Newswise — Johns Hopkins researchers looking to develop a long-acting, injectable malaria preventive using atovaquone have shown in a new study that resistance may not be the challenge scientists thought it was, particularly when using atovaquone as a malaria preventive. Malaria parasites in infected patients being treated with atovaquone tend to develop a resistance to the drug. Because of this, atovaquone by itself is not used as a malaria treatment nor has not been seen as a strong candidate for use as a preventive.

    The study, led by a team of researchers at the Johns Hopkins Malaria Research Institute and the Johns Hopkins University School of Medicine, in conjunction with colleagues at the University of Liverpool, was published online October 12 in Nature Communications. The Malaria Research Institute is based at the Johns Hopkins Bloomberg School of Public Health.

    In their study, the researchers found that the same genetic mutation that renders malaria parasites resistant to atovaquone in patients also destroys the parasite’s ability to live within mosquito hosts—meaning atovaquone-resistant malaria parasites would not be transmissible. The researchers concluded that atovaquone, despite concerns over resistance, holds promise as a long-acting, injectable “chemical vaccine” that could prevent infection in malaria-endemic areas.

    “These findings should reduce concerns about the transmission of atovaquone resistance with atovaquone therapy, particularly when it is used as a chemical vaccine,” says study senior author Theresa Shapiro, MD, PhD, professor of Clinical Pharmacology in the Johns Hopkins University School of Medicine and professor in the W. Harry Feinstone Department of Molecular Microbiology and Immunology at the Bloomberg School.

    Malaria continues to be a major global health burden. According to the World Health Organization, the mosquito-borne parasitic disease afflicted nearly a quarter of a billion people in 2021, killing more than 600,000. Researchers generally agree that, despite the impact of insecticides and other malaria control measures, and the recent development of a malaria vaccine, new approaches against this deadly parasitic pathogen are needed.

    One new approach, described by Shapiro and colleagues at the University of Liverpool in a 2018 preclinical study, would use an injectable, slow-release formulation of atovaquone to provide vaccine-like protection for weeks at a time. Atovaquone is generally considered safe for long-term use even at higher doses, and has the further advantage that it interrupts the malaria life-cycle in human hosts even at the pre-symptomatic stage, when the parasite is developing in liver cells.

    However, when atovaquone is used not as a preventive but as a treatment for symptomatic malaria infection, it often fails due to the emergence of genetically acquired resistance. Shapiro notes that by the time an infection is symptomatic, it involves billions of individual malaria organisms, and in this vast population it is likely that a resistance mutation will appear, if only by random genetic variation. Under atovaquone treatment, parasites with this mutation will come to dominate the infection. Because of the resistance problem, atovaquone is used to treat malaria only in combination with another antimalarial called proguanil.

    Resistance should be much less likely when using atovaquone as a preventive in people who are malaria-free, Shapiro says. The drug in such cases would be acting against a far smaller number of individual parasites that are only in the early, liver-infection stage.

    “In fact, there are no reported cases of atovaquone resistance when the drug has been given prophylactically,” she says.

    Nevertheless, fear of resistance has left a cloud over the drug’s use even as a preventive. Indeed, there have been concerns that the mutation, once it emerged—for example, in a large population treated prophylactically with atovaquone—could spread via human-to-mosquito-to-human transmission.

    In the study, Shapiro’s team examined the resistance problem, focusing on a key resistance mutation, cytochrome-b Y268S, that has been found in clinical investigations involving the major malaria parasite of concern, Plasmodium falciparum. The researchers confirmed that P. falciparum parasites carrying this mutation are thousands of times less susceptible to atovaquone, compared to unmutated parasites.

    However, the scientists also found that the Y268S mutation, while it enables P. falciparum to survive in human hosts being treated with atovaquone, essentially destroys its ability to live within its Anophelesmosquito hosts. This means that atovaquone-resistant mutant parasites cannot spread via transmission from humans to mosquitoes and back again—as the researchers demonstrated using mosquitoes and a P. falciparum-infectable mouse model. For the study, the mice were engrafted with human liver cells and human red blood cells.

    “Testing the mutant parasites for their ability to infect humanized mice is the best in vivo assay we have short of using humans, and strongly supports the inability of drug-resistant parasites to be transmitted by mosquitoes,” says Photini Sinnis, MD, deputy director at the Johns Hopkins Malaria Research Institute and one of the paper’s senior authors.

    The findings suggest that a “chemical vaccine” strategy for protecting people from malaria with atovaquone remains viable and should continue to be investigated. Shapiro and colleagues are collaborating with Andrew Owen, PhD, a professor at the University of Liverpool, and his team to complete preclinical studies and launch a Phase I trial. Owen is principal investigator for LONGEVITY, an international project funded by Unitaid that aims to translate long-acting medicines for malaria and other diseases that disproportionately affect people in low- and middle-income countries.

    “Many advances in malaria medicines that have started at small scale for the protection of travelers, later see wider use in endemic areas where they are most needed—and this may be the path atovaquone takes as a chemical vaccine,” Shapiro says.

    The study’s first author was Victoria Balta, PhD, a graduate student working with coauthor David Sullivan, MD, a professor in the Bloomberg School’s Department of Molecular Microbiology and Immunology.

    Clinically relevant atovaquone-resistant human malaria parasites fail to transmit by mosquito” was co-authored by Victoria A. Balta, Deborah Stiffler, Abeer Sayeed, Abhai Tripathi, Rubayet Elahi, Godfree Mlambo, Rahul Bakshi, Amanda Dziedzic, Anne Jedlicka, Elizabeth Nenortas, Keyla Romero-Rodriguez, Matthew Canonizado, Alexis Mann, Andrew Owen, David Sullivan, Sean Prigge, Photini Sinnis and Theresa Shapiro.

    Funding was provided by Unitaid (2020-38-LONGEVITY); the Johns Hopkins Malaria Research Institute and Bloomberg Philanthropies; and the National Institutes of Health (R01AI132359, R01AI1095453, T32AI138953).

    Disclosures
    Johns Hopkins co-authors Rahul P. Bakshi, Godfree Mlambo, Theresa A. Shapiro, Abhai K. Tripathi, and co-author Andrew Owen of the University of Liverpool, are co-inventors on PCT/GB2017/ 051746 (Atovaquone long-acting injectable formulation).

    Additional author disclosures appear in the Competing interests section at the end of the paper, which is open access.

    # # #

    [ad_2]

    Johns Hopkins Bloomberg School of Public Health

    Source link

  • Operation Warp Speed: The Untold Story of the COVID-19 Vaccine

    Operation Warp Speed: The Untold Story of the COVID-19 Vaccine

    [ad_1]

    The only vaccine candidate that wasn’t fully Slaoui’s choice was AstraZeneca’s. Oxford University, which had a crack vaccine team at its Jenner Institute for Vaccine Research, had already begun a clinical trial for a vaccine it was developing; AstraZeneca was its distribution and manufacturing partner. And the press was already calling the Oxford-AstraZeneca vaccine a winner. That made Azar think about Birx’s demand for a non-mRNA vaccine, so he put Kadlec and Marks in charge of negotiating a deal. On May 21, Operation Warp Speed gave AstraZeneca $1.2 billion in exchange for 300 million doses, so long as its vaccine got FDA approval. That came out to about $4 a dose. (The company insisted that it would not make a profit from the vaccine.)

    When Azar called Trump to tell him about the deal, Trump was furious. “Boris Johnson is going to kill me,” he said, according to someone who was in the room.

    A few days earlier, Moderna announced that its vaccine had generated neutralizing antibodies in eight volunteers. It was a tiny sample, and there was still plenty of skepticism. Nevertheless, Moderna’s stock, which had sold for less than $30 a share back in April, shot up to $80. That evening, the company announced another stock sale. This time, it was able to raise more than $1.3 billion to help jump-start its manufacturing capabilities. In total, Moderna received about $10 billion from the federal government.

    Each company got its own bespoke deal from Slaoui. Sanofi, which was collaborating with GSK, got $2.1 billion for 100 million doses. Johnson & Johnson got $1 billion for 100 million doses.

    As for Pfizer, with 2019 revenue of nearly $52 billion, it didn’t need or want to be part of Warp Speed. It feared that partnering with the government would slow it down. Inside Pfizer, the quest to develop a vaccine with its partner BioNTech was labeled Project Light Speed. “You can have any resources you need, but you need to succeed,” the company’s CEO, Albert Bourla, told his vaccine team. “And by the way,” he added, “my expectations on timeline are far faster than anything you think is actually possible, and you have no excuse not to deliver, because any resource you ask for, you’re going to get.”

    But there was one thing Pfizer needed that only Warp Speed could supply: a guaranteed market. Even mighty Pfizer couldn’t risk shareholders’ wrath by making a huge investment that didn’t pay off. Slaoui took care of that in July, making a deal to pay the company $1.95 billion for 100 million doses. Although Pfizer insists it was not thinking about profits when it began its vaccine work, this deal nonetheless set the price of a dose at close to $20. Moderna’s US price ended up being set around $16.

    Where was Warp Speed’s money coming from? Lacking their own congressionally mandated funds, the team had to scramble. They pulled $10 billion from the CARES Act, which was there thanks to Treasury Secretary Steven Mnuchin, who had added extra money to the Strategic National Stockpile in order to create a slush fund. They also pulled money from the hospital fund established by the CARES Act. “Thank God for Steven,” Azar told a colleague.

    By late May, Slaoui held a virtual meeting with the companies to discuss the next step: the phase three clinical trials. “We are preparing to run what may turn out to be the largest and fastest field efficacy trials…in history,” Slaoui wrote in the invitation to the meeting. The trials would require finding, preparing, vaccinating, and monitoring 120,000 people over six months—or more if Novavax and Sanofi got through their phase two trials. It was important that the group be diverse, given the disproportionate effect of COVID-19 on communities of color.

    In normal circumstances, phase three trials take years. Slaoui wanted them done in a matter of months. In addition to dramatically speeding up the process, Operation Warp Speed had to find and equip all the clinical trial sites with hard-to-obtain personal protective equipment so that everyone involved in the trials would be safe.

    “We basically have to go from an early adolescent company to a full adult company, skipping all of late adolescence,” Moderna’s Juan Andres later told Harvard Business School. Every minute mattered. “I think it would be very difficult to claim that the vaccines would have been developed in this time frame without not just the money but the coordinating role that Warp Speed played,” says Noubar Afeyan, the CEO of Flagship Pioneering, which helped found Moderna. “General Perna and Moncef Slaoui brought a level of expertise and experience and logistical capability and, I’d say, a soft hard touch. A velvet stick, such that people had to behave.”

    [ad_2]

    Joe Nocera, Bethany McLean

    Source link

  • Prior infections and vaccinations affect COVID-19 mutation vulnerability, per study.

    Prior infections and vaccinations affect COVID-19 mutation vulnerability, per study.

    [ad_1]

    Newswise — A person’s immune response to variants of SARS-CoV-2, the virus that causes COVID-19, depends on their previous exposure – and differences in the focus of immune responses will help scientists understand how to optimise vaccines in the future to provide broad protection.

    A new study has found that people differ in how vulnerable they are to different mutations in emerging variants of SARS-CoV-2.

    This is because the variant of SARS-CoV-2 a person was first exposed to determines how well their immune system responds to different parts of the virus, and how protected they are against other variants.

    It also means that the same COVID-19 vaccine might work differently for different people, depending on which variants of SARS-CoV-2 they have previously been exposed to and where their immune response has focused.

    The discovery underlies the importance of continuing surveillance programmes to detect the emergence of new variants, and to understand differences in immunity to SARS-CoV-2 across the population.

    It will also be important for future vaccination strategies, which must consider both the virus variant a vaccine contains and how immune responses of the population may differ in their response to it.

    “It was a surprise how much of a difference we saw in the focus of immune responses of different people to SARS-CoV-2. Their immune responses appear to target different specific regions of the virus, depending on which variant their body had encountered first,” said Dr Samuel Wilks at the University of Cambridge’s Centre for Pathogen Evolution in the Department of Zoology, first author of the report.

    He added: “Our results mean that if the virus mutates in a specific region, some people’s immune system will not recognize the virus as well – so it could make them ill, while others may still have good protection against it.”

    The research, published today in the journal Science, involved a large-scale collaboration across ten research institutes including the University of Cambridge and produced a comprehensive snapshot of early global population immunity to COVID-19.

    Researchers collected 207 serum samples – extracted from blood samples – from people who had either been infected naturally with one of the many previously circulating SARS-CoV-2 variants, or who had been vaccinated against SARS-CoV-2 with different numbers of doses of the Moderna vaccine.

    They then analysed the immunity these people had developed, and found significant differences between immune responses depending on which variant a person had been infected with first.

    “These results give us a deep understanding of how we might optimise the design of COVID-19 booster vaccines in the future,” said Professor Derek Smith, Director of the University of Cambridge’s Centre for Pathogen Evolution in the Department of Zoology, senior author of the report.

    He added: “We want to know the key virus variants to use in vaccines to best protect people in the future.”

    The research used a technique called ‘antigenic cartography’ to compare the similarity of different variants of the SARS-CoV-2 virus. This measures how well human antibodies, formed in response to infection with one virus, respond to infection with a variant of that virus. It shows whether the virus has changed enough to escape the human immune response and cause disease.

    The resulting ‘antigenic map’ shows the relationship between a wide selection of SARS-CoV-2 variants that have previously circulated. Omicron variants are noticeably different from the others – which helps to explain why many people still succumbed to infection with Omicron despite vaccination or previous infection with a different variant.

    Immunity to COVID-19 can be acquired by having been infected with SARS-CoV-2 or by vaccination. Vaccines provide immunity without the risk from the disease or its complications. They work by activating the immune system so it will recognise and respond rapidly to exposure to SARS-CoV-2 and prevent it causing illness. But, like other viruses, the SARS-CoV-2 virus keeps mutating to try and escape human immunity.

    During the first year of the pandemic, the main SARS-CoV-2 virus in circulation was the B.1 variant. Since then, multiple variants emerged that escaped pre-existing immunity, causing reinfections in people who had already had COVID.

    “The study was an opportunity to really see – from the first exposure to SARS-CoV-2 onwards – what the basis of people’s immunity is, and how this differs across the population,” said Wilks.

    [ad_2]

    University of Cambridge

    Source link

  • It’s October and it’s not too late to get a flu shot

    It’s October and it’s not too late to get a flu shot

    [ad_1]

    BYLINE: Eric Gorton, media relations coordinator

    HARRISONBURG, Va. — About a month into flu season JMU professor Suzanne Grossman says it is not too late to get a flu shot.

    “I get the flu shot every year and I usually get that sometime in October,” she said.

    As the months get colder viruses spread rapidly, said Grossman, a professor of health sciences who teaches a class on infectious diseases. “This means people are closer together, which increases the likelihood that the virus will spread and also because it’s cooler outside, we’re not opening windows and having better ventilation, which can also increase the spread of the virus,” she said.

    In addition to flu and the common cold, COVID cases are on the rise. Grossman said the newest vaccine is effective against the latest subvariant and is recommended for people who have not had the virus or the shot in the last two months.

    When talking about vaccine effectiveness Grossman offered, “They’re especially effective in preventing against severe illness as well as hospitalization and death. So, people who are vaccinated might still get ill with COVID or the flu but the illness that they get will likely be much less severe than if they hadn’t been vaccinated against the flu or COVID.” 

    There’s no vaccine for the common cold, but there are measures to help protect against it. Grossman suggests washing hands, covering your nose and mouth when coughing or sneezing, and wearing a mask if you must go out.

    Audio of Grossman’s comments is here: https://www.dropbox.com/scl/fi/qwaq5zalj5prw0nyvbtxx/230929-Grossman-update-clips.wav?rlkey=hzhksgw0tswsuml0r5mmoud12&dl=0

    A transcript of her comments is here: https://www.dropbox.com/scl/fi/axexlmnb551et5tk1qurw/230928-Grossman-transcript-flu-season.docx?rlkey=st8inzpracnnd17ivskgw6o5k&dl=0

     

    ###

    [ad_2]

    James Madison University

    Source link

  • Nobel Prize in medicine awarded to two scientists whose work enabled creation of mRNA vaccines against COVID-19

    Nobel Prize in medicine awarded to two scientists whose work enabled creation of mRNA vaccines against COVID-19

    [ad_1]

    STOCKHOLM (AP) — Two scientists won the Nobel Prize in medicine on Monday for discoveries that enabled the development of effective mRNA vaccines against COVID-19.

    The award was given to Katalin Karikó, a professor at Sagan’s University in Hungary and an adjunct professor at the University of Pennsylvania, and Drew Weissman, who performed his prizewinning research together with Karikó at the University of Pennsylvania.

    “Through their groundbreaking findings, which have fundamentally changed our understanding of how mRNA interacts with our immune system, the laureates contributed to the unprecedented rate of vaccine development during one of the greatest threats to human health in modern times,” the panel that awarded the prize said.

    Thomas Perlmann, secretary of the Nobel Assembly, announced the award and said both scientists were “overwhelmed” by news of the prize when he contacted them shortly before the announcement.

    The Nobel Prize in physiology or medicine was won last year by Swedish scientist Svante Paabo for discoveries in human evolution that unlocked secrets of Neanderthal DNA which provided key insights into our immune system, including our vulnerability to severe COVID-19.

    The award was the second in the family. Paabo’s father, Sune Bergstrom, won the Nobel Prize in medicine in 1982.

    Nobel announcements continue with the physics prize on Tuesday, chemistry on Wednesday and literature on Thursday. The Nobel Peace Prize will be announced Friday and the economics award on Oct. 9.

    The prizes carry a cash award of 11 million Swedish kronor ($1 million). The money comes from a bequest left by the prize’s creator, Swedish inventor Alfred Nobel, who died in 1896.

    The prize money was raised by 1 million kronor this year because of the plunging value of the Swedish currency.

    The laureates are invited to receive their awards at ceremonies on Dec. 10, the anniversary of Nobel’s death. The prestigious peace prize is handed out in Oslo, according to his wishes, while the other award ceremony is held in Stockholm.

    Corder reported from The Hague, Netherlands.

    [ad_2]

    Source link

  • Scientists who paved way for COVID-19 mRNA vaccines win Nobel prize

    Scientists who paved way for COVID-19 mRNA vaccines win Nobel prize

    [ad_1]

    Katalin Karikó and Drew Weissman have been awarded the Nobel prize in medicine for their work on messenger RNA technology, which enabled the development of the first vaccines against COVID-19.

    The Nobel Assembly at Sweden’s Karolinska Institute, which is responsible for selecting the winner of one of science’s most prestigious prizes, said on Monday that the discoveries “were critical for developing effective mRNA vaccines against COVID-19.”

    mRNA vaccines work by delivering into the body genetic instructions for building proteins that are present in the virus being immunized against. That spurs cells to create those proteins, which the body then recognizes as foreign and attacks; training the immune system and creating protection against the actual virus.

    In the early 1990s, Karikó, from Hungary, was working at the University of Pennsylvania looking at how mRNA could be used in medicine. She was joined in her research by U.S. colleague Weissman, an immunologist specializing in dendritic cells, which are responsible for the body’s immune response during vaccination.

    Together, the scientists discovered how to alter mRNA so that it wasn’t immediately detected by the body’s immune system and could deliver its payload to the target cells. Further work by the pair improved the efficiency of mRNA, so that it stimulated more protein production.

    “Through their discoveries that base modifications both reduced inflammatory responses and increased protein production, Karikó and Weissman had eliminated critical obstacles on the way to clinical applications of mRNA,” said the Nobel Assembly.

    As well as laying the groundwork for mRNA vaccines, Karikó was employed from 2013 to 2022 at vaccine developer BioNTech, which, together with Pfizer, produced the first COVID-19 vaccine approved in the EU.

    Pharma companies are now developing mRNA vaccines and therapies for a swathe of different diseases including flu, tuberculosis, HIV, malaria, Lyme disease, Zika and various types of cancer.

    The award comes with a cash prize of 11 million Swedish krona (€950,000). In 1951, Max Theiler won the prize for his work helping discover the vaccine against yellow fever.

    [ad_2]

    Carlo Martuscelli

    Source link

  • Why dengue in Europe could spell disaster for the rest of the world 

    Why dengue in Europe could spell disaster for the rest of the world 

    [ad_1]

    Press play to listen to this article

    Voiced by artificial intelligence.

    In the early morning of the last day of August, Parisians experienced for the first time a practice normally confined to tropical regions — authorities fumigating the city against the tiger mosquito. The event was a tangible confirmation of what public health stats already showed: Dengue, the deadly mosquito-borne disease, had well and truly arrived in Europe. 

    In 2022, Europe saw more cases of locally acquired dengue than in the whole of the previous decade. The rise marks both a public health threat and a corresponding market opportunity for dengue vaccines and treatments; news that should spur the pharma industry to boost investment into the neglected disease. 

    On the face of it, this shift would appear to benefit not only countries like France but also nations like Bangladesh and the Philippines that have long battled dengue.

    But that assumption could be fatally flawed, experts told POLITICO. 

    People working in the field say the rise of dengue in the West could, in fact, make it harder to get lifesaving drugs to those who need them most, because pharma companies develop tools that are less effective in countries where the dengue burden is the highest or because wealthy nations end up hoarding these medicines and vaccines. 

    “It might look like a good thing — and it is a good thing — that we’re getting more products developed, but does it then create a two-tier system where high-income populations get access to it and then we still have the access gap for low- and middle- income countries?” asked Lindsay Keir, director of the science and policy advisory team at think tank Policy Cures Research.

    Killer invading mosquitoes

    Climate change and migration mean the mosquitoes that transmit dengue, as well as other diseases such as chikungunya and Zika, are setting up shop in Europe. The most recent annual data from the European Centre for Disease Prevention and Control shows that, in 2022, Europe saw 71 cases of locally acquired dengue: 65 in France and six in Spain.

    While dengue usually results in mild or no symptoms, it can also lead to high fever, severe headache and vomiting. Severe dengue can cause bleeding from the gums, abdominal pain and, in some cases, death.

    So far, the mosquito has mostly been confined to Southern Europe but it’s a worry across the Continent. In Belgium, the national public health research institute Sciensano has even launched an app where members of the public can submit photos of any Asian tiger mosquitos they spot.

    The diseases spread by these mosquitoes have traditionally fallen under the umbrella of neglected tropical diseases, a group of infections that affect mainly low-income countries and struggle to attract research and development investment. But this is changing.

    Policy Cures Research, which publishes an annual report on R&D investment into neglected diseases, removed dengue vaccines from their assessment in 2013. Dengue was no longer seen as an area where there was market failure, due to the emergence of a market that the private sector could tap into. 

    The organization is still tracking dengue drugs and biologics and their 2022 analysis showed a 33 percent increase in funding for research into non-vaccine products compared to the previous year, with industry investment reaching a record high of $28 million. 

    Climate change and migration mean the mosquitoes that transmit dengue, as well as other diseases such as chikungunya and Zika, are setting up shop in Europe | Lukas Schulze/Getty Images

    Sibilia Quilici, executive director of the vaccine maker lobby group Vaccines Europe, said the most recent pipeline review of members found that roughly 10 percent were targeting neglected diseases. There is more R&D happening in this area, said Quilici.

    Across the major drugmakers, J&J is working on a dengue antiviral treatment and MSD has a dengue vaccine in their pipeline, while Sanofi has a second yellow fever jab in development. Two dengue vaccines are already approved in the EU — one from Sanofi and another from Takeda. Moderna recently told POLITICO that it is looking closely at a dengue vaccine candidate and it already has a Zika candidate in the works. 

    For the few, not the many

    But just because there might soon be larger markets for Big Pharma doesn’t mean the products will be suitable for the populations that have been waiting years for these tools. 

    Rachael Crockett, senior policy advocacy manager at the non-profit Drugs for Neglected Diseases initiative (DNDi), said increased pharma investment in a particular disease won’t necessarily lead to products developed that are globally relevant. “Industry will — and governments are also more likely to — focus on prevention,” she said.

    That means tools such as vaccines will be prioritized; but in countries where dengue is endemic, the rainy season completely overburdens their health systems and what they desperately need are treatments, said Crockett.  

    She also said a massive increase in investment without a structure to ensure access to resulting products means “we have absolutely no guarantee that there isn’t going to be hoarding, [that] there isn’t going to be high prices.” Case in point: The U.S. national stockpile of Ebola vaccines, which exists despite there never having been an Ebola outbreak in the country.

    But just because there might soon be larger markets for Big Pharma doesn’t mean the products will be suitable for the populations that have been waiting years for these tools | Noel Celis/AFP via Getty Images

    Underlying many of these fears are the mistakes of the COVID-19 pandemic, which saw countries with less cash and political heft at the back of the queue when it came to vaccines.

    Lisa Goerlitz, head of German charity Deutsche Stiftung Weltbevölkerung (DSW)’s Brussels office, warned if drug development picks up because of a growing market in high-income countries, then accessibility, affordability and other criteria that make it suitable for low resource settings might not be prioritized.

    Vaccines Europe’s Quilici sought to allay these concerns, pointing to the pharma industry’s Berlin Declaration, a proposal to reserve an allocation of real-time production of vaccines in a health crisis. Quilici said this was a “really strong commitment …which comes right from the lessons learnt from COVID-19 and which could definitely overcome the challenges we had during the pandemic, if it is taken seriously.”

    CORRECTION: This article has been updated to correct the spelling of Lisa Goerlitz.

    [ad_2]

    Ashleigh Furlong

    Source link